(Bellou et al., 2013; Shojaei, 2012) Inhibition of ‘over‐expressed’ proteins within the tumor – in the absence of genomic aberration of that protein – has less supporting evidence in general, but has shown benefit in randomized phase II settings, such as selection of Met expressing tumors for anti‐MET therapies for gastroesophageal cancer (GEC), (Catenacci et al., 2011a; Iveson et al., 2014) or ATM expression and its potential relevance to PARP inhibition in GEC. Here, MET is linked to neoplasm.